SYK at a glance
Stryker Corporation (SYK, SEC CIK 310764) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Stryker Corporation (SYK) reported revenue of $25.1 billion (up 11.2% from FY2024) and net income of $3.2 billion. Diluted EPS was $8.40.
- As of September 30, 2026, 55 institutional investment managers tracked by SignalX reported holding Stryker Corporation (SYK) shares worth $35.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by STRYKER RONDA E on November 6, 2026 of 10,587 shares at $327.69 per share.
- In the last 90 days, SYK insiders reported 0 open-market purchases ($0) and 6 open-market sales ($178.9M) on Form 4, a net sale of $178.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $25.1B
- +11.2% vs prior year
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$178.9M
- 13F holders
- 55 funds
- $35.7B · −7 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 5.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- Regulatory risk: EU medical device regulations require costly quality system updates, labeling changes, and remanufacturing impacting R&D and compliance expenses in 2025
- Geopolitical/macroeconomic risk: Foreign currency fluctuations affected net sales by ±0.5%, with 10.7% growth in constant currency highlighting sensitivity to exchange rates
- Operational risk: Inventory stepped up to fair value increased amortization expenses by $173M in 2025, reflecting acquisition integration supply chain complexity
- Competitive risk: Sales growth slowdown in Orthopaedics segment (4.3% in 2025 vs 8.9% in 2024) signals risk from market competition affecting higher-margin segment
- Financial risk: Increased interest expense to $607M in 2025 due to $3.0B revolving credit facility and $3.0B commercial paper limit raising leverage and refinancing needs
Business Overview
- Core business model focused on medical technology and device manufacturing, emphasizing innovation and compliance
- No new products, services, or segments explicitly introduced or emphasized in the 2026 filing
- Continued adherence to corporate governance enhancements, including adoption of updated Insider Trading Policies and transparency practices
- Equity compensation plans with 36.5 million shares authorized for issuance, including 11.2 million options outstanding at $234.56 average exercise price
- Noteworthy emphasis on proxy statement incorporation by reference for governance, compensation, and related-party matters instead of detailed disclosures within the filing
Management Discussion & Analysis
- Revenue $18.0B, up 9% YoY driven by MedSurg and Neurotechnology segment growth
- Operating margin 22.5% vs 21.0% YoY due to product mix and cost management
- MedSurg and Neurotechnology segment revenue $11.2B up 12%, Orthopaedics $6.8B up 4%
- Cash flow from operations $3.2B; capital allocation: $1.0B acquisitions, $0.5B dividends, $0.8B share repurchases
- Management highlights risks from tariffs, inflation, and geopolitical issues impacting costs and demand
AI summary of the SYK 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to 2025 Form 10-K risk factors
- No material changes from March 31, 2026 Form 10-Q risk factors
Management Discussion & Analysis
- Revenue $6,520M, up 7.7% YoY from $6,057M, driven by increased unit volume
- Operating margin 15.9% vs 18.7% YoY, adjusted margin 26.2% vs 25.6%
- Best segment: MedSurg and Neurotechnology sales up 9.2%, margin 28.7% vs 26.1%
- Worst segment: Orthopaedics sales up 5.7%, margin 31.2% vs 32.4%
- Operating cash flow $3,303M vs $2,901M; $1,000M debt repayment, $1,000M share repurchases, dividends
- Peripheral Vascular supply constraints and slower recovery triggered a $293M goodwill impairment charge
AI summary of the SYK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from 11 to 12 directors, increasing governance capacity and adding an independent healthcare executive
- James E. Davis joins effective January 1, 2027, bringing CEO experience at Quest Diagnostics and prior medical-device leadership
Item 7.01: Regulation FD Disclosure
- Stryker elected Mr. Davis to its board, expanding or changing board oversight
- Exhibit 99.1 contains the company’s announcement and related director details
Item EX-99.1: Item EX-99.1
- Board nomination of Jim Davis effective January 1, 2027, pending election
- Davis brings CEO experience at Quest Diagnostics and prior leadership of GE’s MRI business
Item 2.02: Results of Operations and Financial Condition
- Third-quarter 2026 operating results announced October 29, 2026
- Detailed financial results and management commentary contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 net sales $6.5B, up 7.7%, with organic growth entirely volume-driven
- MedSurg and Neurotechnology growth 9.1%, outperforming Orthopaedics at 5.9%
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO Kevin Lobo resigns December 31, 2026, becoming Executive Chair January 1, 2027, supporting leadership continuity
- President and COO Spencer Stiles appointed CEO and director January 1, 2027, expanding the Board from 10 to 11 members
Item EX-99.1: Item EX-99.1
- CEO Kevin Lobo transitions to Executive Chair; Spencer Stiles becomes CEO and joins the Board January 1, 2027
- Planned internal succession preserves leadership continuity, with Stiles bringing nearly three decades across Stryker businesses
Item 7.01: Regulation FD Disclosure
- Stryker announced a leadership transition on October 6, 2026
- Related infographics accompany the announcement as Exhibits 99.1, 99.2 and 99.3
AI summaries of SYK 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SYK
Don't miss the next SYK filing
- Alerts as it files. A push when SYK files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SYK, by share count.
- Ask anything. An AI agent that reads every SYK filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| STRYKER RONDA E | M | Nov 19, 2026 | 3,605 | $122.51 |
| STRYKER RONDA E | M | Nov 19, 2026 | 3,605 | - |
| STRYKER RONDA E | Sell | Nov 6, 2026 | 10,587 | $327.69 |
| STRYKER RONDA E | Sell | Nov 6, 2026 | 131,707 | $324.09 |
| STRYKER RONDA E | Sell | Nov 6, 2026 | 149,357 | $325.97 |
| STRYKER RONDA E | Sell | Nov 6, 2026 | 82,089 | $327.03 |
| STRYKER RONDA E | Sell | Nov 6, 2026 | 142,794 | $325.11 |
| STRYKER RONDA E | Sell | Nov 6, 2026 | 33,466 | $323.19 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $22.6B | $25.1B |
| Gross Profit | - | $14.4B | $16.1B |
| Operating Income | - | $3.7B | $4.9B |
| Net Income | - | $3.0B | $3.2B |
| Gross Margin | - | 63.9% | 64.0% |
| Op. Margin | - | 16.3% | 19.5% |
| Net Margin | - | 13.2% | 12.9% |
| Balance Sheet | |||
| Total Assets | $39.9B | $43.0B | $47.8B |
| Equity | $18.6B | $20.6B | $22.4B |
| ROE | - | 14.5% | 14.5% |
| Per Share | |||
| EPS | - | $7.76 | $8.40 |
| Cash Flow | |||
| Operating CF | - | $4.2B | $5.0B |
| CapEx | - | $755.0M | $761.0M |
Source: XBRL data in Stryker Corporation (SYK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SYK share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 55 | $35.70B |
| Q2 2026 | 62 | $45.07B |
| Q1 2026 | 61 | $45.50B |
| Q4 2025 | 58 | $47.74B |
| Q3 2025 | 63 | $56.45B |
| Q2 2025 | 62 | $56.59B |
| Q1 2025 | 58 | $39.08B |
| Q4 2024 | 55 | $29.00B |
- Ameriprise Financial+1.22M (+37%)
- D.E. Shaw & Co+511.6K (+189%)
- Invesco Ltd+459.9K (+25%)
- State Street Corp+267.0K (+2%)
- Vanguard Capital Management LLC+183.4K (+1%)
- JPMorgan Chase & Co−4.98M (-29%)
- T. Rowe Price Group−4.69M (-39%)
- Bank of America Corp−1.96M (-44%)
- Morgan Stanley−821.1K (-14%)
- Franklin Resources−516.2K (-19%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 474 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SYK filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Oct 30, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 8-K | Oct 6, 2026 | - | Analysis | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 10-Q | Jul 31, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 8-K | May 20, 2026 | - | Analysis | |
| 4 | May 12, 2026 | - | - | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
SYK SEC filings: frequently asked questions
Are SYK insiders buying or selling?
In the last 90 days, Stryker Corporation (SYK) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $178.9 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SYK stock?
As of September 30, 2026, the largest Stryker Corporation (SYK) holders among the 13F filers tracked by SignalX were BlackRock ($7.5 billion), Vanguard Capital Management LLC ($6.3 billion), State Street Corp ($4.4 billion), JPMorgan Chase & Co ($3.4 billion), Vanguard Portfolio Management LLC ($2.2 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SYK's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Stryker Corporation (SYK) reported revenue of $25.1 billion (up 11.2% from FY2024) and net income of $3.2 billion. Diluted EPS was $8.40. The figures come from the XBRL data in the 10-K.
What are the main risks in SYK's latest 10-K?
In the 10-K filed February 11, 2026, Stryker Corporation (SYK) flagged: Regulatory risk: EU medical device regulations require costly quality system updates, labeling changes, and remanufacturing impacting R&D and compliance expenses in 2025. Geopolitical/macroeconomic risk: Foreign currency fluctuations affected net sales by ±0.5%, with 10.7% growth in constant currency highlighting sensitivity to exchange rates. (AI summary of the Risk Factors section.)
What did SYK report in its latest 8-K?
Stryker Corporation (SYK) filed an 8-K on November 9, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 7.01 (Regulation FD Disclosure). Board expanded from 11 to 12 directors, increasing governance capacity and adding an independent healthcare executive.
What are the latest SYK SEC filings?
Stryker Corporation (SYK) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 20, 2026.
What is SYK's SEC CIK number?
Stryker Corporation (SYK)'s SEC Central Index Key (CIK) is 310764. EDGAR lists every SYK filing under that number.
Ask anything about SYK
The research agent reads SYK's filings, financials, insider trades and 13F holders, then answers with sources.